Who Supplies Amphotericin to India from UNITED STATES MINOR OUTLY

To import finished pharmaceutical formulations containing Amphotericin into India, the foreign manufacturer must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This process involves registering the manufacturing premises and the specific drug product. The registration certificate is valid for three years from the date of issue. The application must include a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and a Free Sale Certificate from the country of origin. The application process typically takes several months, depending on the completeness of the submitted documentation.

Imported pharmaceutical formulations are subject to quality testing by CDSCO-approved laboratories in India. Three consecutive batches must be submitted for testing, with each batch accompanied by a Certificate of Analysis (CoA) from the exporting country’s laboratory. The testing includes stability studies in accordance with ICH Zone IV guidelines. Port inspection by customs drug inspectors is mandatory to ensure compliance with Indian Pharmacopoeia standards. If a batch fails the quality test, it may be rejected, and the importer may be required to re-export or destroy the product.

In April 2025, the CDSCO mandated that all imported drugs, including finished formulations, must have an Import Registration Certificate and license. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy also stipulates that banned drugs manufactured in Special Economic Zones (SEZ) for export purposes are not allowed for transfer to the Domestic Tariff Area (DTA) for any purpose.

India imports finished Amphotericin formulations to meet the demand for specific dosage forms and patented or branded products not manufactured domestically. The domestic pharmaceutical industry may lack the capacity or technology to produce certain Amphotericin formulations, leading to reliance on imports. The market size for Amphotericin formulations in India is substantial, with imports contributing to the availability of these essential medicines.

The import duty structure for finished pharmaceutical formulations under HS Code 30049029 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10%, and an Integrated Goods and Services Tax (IGST) that varies based on the specific product. There are no exemptions or preferential duty rates for imports from the United States Minor Outlying Islands. The total landed duty percentage depends on the CIF (Cost, Insurance, and Freight) value and the applicable IGST rate.

India sources finished Amphotericin formulations from the United States Minor Outlying Islands due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Other suppliers include China, Germany, and the United States. The United States Minor Outlying Islands' share in the Indian market is limited but significant for specific products.

India imports finished Amphotericin formulations from the United States Minor Outlying Islands due to the availability of specific patented formulations, specialized dosage forms, and high-quality manufacturing standards not present in the domestic market. These imports fulfill the demand for products that are essential for treating certain medical conditions but are not produced locally.

Compared to other origins like China, the European Union, and the United States, the United States Minor Outlying Islands offers unique advantages in terms of specific formulations and quality standards. While other countries may offer competitive pricing, the United States Minor Outlying Islands' products are distinguished by their compliance with stringent regulatory standards and specialized formulations.

Importing finished Amphotericin formulations from the United States Minor Outlying Islands involves risks such as single-source dependency, currency fluctuations, regulatory changes, and potential shipping disruptions. Past shortages have been minimal, but any disruption in the supply chain could impact the availability of these critical medicines in the Indian market.

1. 1Dual-Sourcing: Engage with multiple suppliers to mitigate the risk of supply chain disruptions.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against potential delays.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.
5. 5Regulatory Compliance: Stay updated on import regulations and ensure all necessary licenses and certifications are in place.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/41: Submit the application for registration of the manufacturing premises and the drug product.
3. 3Import Registration Certificate: Obtain the certificate from CDSCO for the specific drug product.
4. 4No Objection Certificate (NOC): If applicable, obtain an NOC from the Ministry of Environment and Forests for environmental clearance.
5. 5Customs Broker: Engage a licensed customs broker to facilitate the import process.
6. 6Advance Ruling: Seek an advance ruling from the Authority for Advance Rulings on classification and duty